Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiovascular Diseases Digestive System Diseases Fatty Liver Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Liver Diseases Metabolic Diseases Metabolic Syndrome Non-Alcoholic Fatty Liver Disease Nutritional and Metabolic Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

NUS

Singapore

Location status: Recruiting

Location contact

Hayang Yang, PhD

CONTACT

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

40-70 years old
ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion criteria

Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
Limited life expectancy
Other ongoing unstable medical conditions
Pregnant women

Treatment and study plan

Digital wearable and AI-human symbiotic lifestyle intervention

Behavioral

Digital wearable and AI-human symbiotic lifestyle intervention

Primary outcomes

Major adverse cardiovascular event

Time frame: 5 years

Composite of cardiac death, non-fatal myocardial infarction, resuscitated cardiac arrest, non-fatal ischemic stroke, congestive heart failure, coronary revascularization

Study contacts

Contact information is provided by the study sponsor or research team.

Hayang Yang, PhD

CONTACT

[email protected]

+6582810448

Sponsors and collaborators

Lead sponsor

National University Hospital, Singapore

Other

Collaborators

National University of Singapore

Registry information

Acronym: RESET

Important dates

Study start: 2024
Primary completion: 2029
Study completion: 2030
First posted: Jan 18, 2024
Registry last updated: Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting